Elicera Therapeutics plans first ELC-401 glioblastoma clinical trial after positive Swedish MPA feedback

Reuters2026/08/28 06:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Elicera Therapeutics flagged plans for a first clinical study of CAR T candidate ELC-401 in glioblastoma; trial design is being finalized.
No trial results were presented for ELC-401; regulatory feedback indicated the preclinical package supports starting clinical development.
Separately, results were already presented from the CARMA study of ELC-301, showing broad tumor control with responses that appear durable.
Funding from a rights issue, raising SEK 54.6 million before costs, is intended to support CARMA enrollment and accelerate ELC-401 readiness.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicera Therapeutics AB published the original content used to generate this news brief on August 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Elicera Therapeutics plans first ELC-401 glioblastoma clinical trial after positive Swedish MPA feedback

You may also like

Crypto prices